Fengyu Capital Leads Series A Investment in Dailai Technologies to Advance Non-Invasive Neuromodulation for Parkinson’s Disease

July 17, 2024Fengyu Capital Completes the First Round of Investment in Beijing Dalai Technology Co., Ltd.。, jointly initiated by several of the world's top neurology clinical experts,Dedicated to pioneering a new modality for the full-life-cycle intervention and management of Parkinson's patients outside the hospital through non-invasive neuromodulation and monitoring products, achieving more effective coordination between in-hospital and out-of-hospital care.The Company's First Heavyweight ProductForParkinson's FreezeGaitSensory Intelligent Stimulation Shoes for Motor Function Improvement, currentlyPreliminary patient data has been accumulated, demonstrating superior improvement in motor function clinically.。

Company Business Model Diagram

Unmet clinical needs remain in the intervention and management of Parkinson's disease. As a first-line treatment, drugs exhibit "wearing-off" and "on-off" phenomena, and the motor symptoms of patients in the middle to late stages are not well controlled. Invasive surgeries, on the other hand, carry significant trauma and multiple side effects.Against the backdrop of an aging population, extended lifespans of Parkinson's patients, and an increasing pursuit of quality of life, non-invasive wearable diagnostic and therapeutic devices can manage chronic conditions by addressing various motor symptoms of Parkinson’s disease—such as tremors, rigidity, and freezing of gait—through more effective and personalized regulation and intervention. This approach establishes a new model for full-lifecycle intervention and management for Parkinson’s patients.

In the past, non-invasive wearable devices for Parkinson's diagnosis and treatment have only been developed and validated at small-scale laboratory levels, lacking large-scale validation studies to prove their effectiveness. However, with...Cala Health's Cala Trio, with its large-scale clinical validation for tremor improvement and FDA approval, along with Charco Neurotech's CUE1, which has shown preliminary efficacy in a pilot study, non-invasive Parkinson's assistive devices are gradually gaining recognition from doctors and patients worldwide.

Beijing Dalai Technology Co., Ltd. has combined the team's many years of clinical experience to propose a new "peripheral vibration somatosensory stimulation-coordinated reset" hypothesis, and developed an exclusive wearable product for peripheral nerve modulation. Relevant clinical research findings are about to be published in a top journal in this field.Unlike the more common tremor-improving or monitoring Parkinson's wearable devices on the market, this product directly addresses the pain point of freezing of gait, which is difficult to solve with medication and ordinary wearable devices, offering significant market potential. Meanwhile, the company has developed a series of wearable neuromodulation products targeting various motor and non-motor symptoms of Parkinson’s disease, aiming to achieve full lifecycle intervention and management of the condition, enhancing patients' quality of life in multiple aspects.

The funds raised from this financing by Beijing Dalai Technology Co., Ltd. will be used forProduct Development, Registration, Team Expansion, and Production Center Construction, advancing the clinical trials and certification of core products to lay the foundation for subsequent industrial sales.

• Recommended Reading

---

• About Fengyu
  

Fengyu Capital is a dual-currency equity investment firm focused on the medical and technology sectors, with offices in Beijing, Shanghai, and Hong Kong. Fengyu CapitalThe core team has been cooperating for over 10 years, possessing extensive management experience in both RMB funds and US dollar funds, with a scale of managed assets exceeding 8 billion yuan in the past. They have abundant industrial resources in the medical and technology fields. Adhering to the investment philosophy of continuous focus, precise layout, and deep industry cultivation, the Fengyu team has delivered stable and sustained excellent returns to investors over the past decade, gaining continuous recognition from multiple institutional investors both domestically and internationally.

Fengyu Capital insists on empowering invested enterprises in an all-round way from the aspects of industry-university-research cooperation, clinical resources, sales resources, regulatory resources, etc., acting as a partner to the invested enterprises and helping them grow with the most professional capabilities. Past star cases include Sonoscape (Stock Code:300633, Leader in medical ultrasound and endoscope equipment),DJI Innovations (The world's leading drone brand), Transsion Holdings (Stock Code: 688036，The largest mobile phone brand in Africa)、Ronbay Lithium (Stock Code: 688005, China's R&D and manufacturing enterprise for cathode materials of power lithium batteries), YHJY (Stock Code: 301367, the leading brand of home respiratory equipment in China), etc.